{"product_id":"xers-marketing-mix","title":"(XERS) Xeris Biopharma Holdings, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Xeris Biopharma Holdings, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing, distribution, and promotion for its injectable and specialty pharma portfolio and shows a real sample of the report on this page. Purchase the full version to download the complete ready-to-use analysis for presentations, strategy, or research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 marketed therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc.’s commercial base rests on 3 marketed therapies: Gvoke, Keveyis, and Recorlev. Gvoke treats severe hypoglycemia, Keveyis treats primary periodic paralysis, and Recorlev treats endogenous hypercortisolemia in Cushing’s syndrome. This is a clear rare-disease and specialty-care mix, built around high-need, low-frequency conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGvoke glucagon rescue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGvoke is Xeris Biopharma Holdings, Inc.'s ready-to-administer liquid glucagon for severe hypoglycemia, approved for patients 2 years and older. It skips reconstitution, so caregivers can give 1 dose fast in an emergency. That matters in diabetes care, where seconds count and delayed treatment can raise hospital risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeveyis periodic paralysis therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeveyis (dichlorphenamide) treats hyperkalemic, hypokalemic, and related primary periodic paralysis in a small, specialist-managed rare-disease market, so promotion is focused on neuromuscular experts rather than mass prescribing.\u003c\/p\u003e\n\u003cp\u003eFor Xeris Biopharma Holdings, Inc., Keveyis strengthens the neurology and rare-disease franchise and adds a differentiated branded asset in a niche with limited direct competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRecorlev Cushing’s syndrome treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecorlev is Xeris Biopharma Holdings, Inc.’s oral cortisol synthesis inhibitor for adult patients with endogenous hypercortisolemia from Cushing’s syndrome. It strengthens the endocrinology franchise and fits the Product part of the mix with a specialist-led, chronic-care use case.\u003c\/p\u003e\n\u003cp\u003eIn 2025, the therapy kept targeting a rare, high-need disease area with long treatment duration and close monitoring, which supports repeat prescribing and specialty channel demand. The positioning is clear: manage cortisol over time, under endocrinologist supervision.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral cortisol synthesis inhibitor\u003c\/li\u003e\n\u003cli\u003eAdult Cushing’s syndrome use\u003c\/li\u003e\n\u003cli\u003eEndocrinology franchise anchor\u003c\/li\u003e\n\u003cli\u003eSpecialist-managed chronic therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e2 proprietary platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris’ two proprietary platforms, XeriSol and XeriJect, are built to improve drug delivery by enabling ready-to-use liquid and injectable formulations. They support lifecycle management by helping extend existing products and create new ones, which widens the development pipeline. Xeris’ 2024 annual report said its portfolio included multiple commercial products built on these platforms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eXeriSol and XeriJect are core formulation tools\u003c\/li\u003e\n\u003cli\u003eThey improve delivery and usability\u003c\/li\u003e\n\u003cli\u003eThey help extend product life cycles\u003c\/li\u003e\n\u003cli\u003eThey support new product creation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris Biopharma’s Rare-Disease Trio: Gvoke, Keveyis, and Recorlev\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc.’s Product mix centers on 3 rare-disease brands: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use glucagon for severe hypoglycemia; Keveyis treats primary periodic paralysis; Recorlev treats endogenous Cushing’s syndrome. Its XeriSol and XeriJect platforms support ready-to-use formulations and pipeline extension.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGvoke\u003c\/td\u003e\n\u003ctd\u003eSevere hypoglycemia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeveyis\u003c\/td\u003e\n\u003ctd\u003ePrimary periodic paralysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecorlev\u003c\/td\u003e\n\u003ctd\u003eCushing’s syndrome\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific 4P’s analysis of Xeris Biopharma’s Product, Price, Place, and Promotion strategies, grounded in real-world market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses Xeris Biopharma’s 4Ps into a quick, pain-point-relieving snapshot for faster strategic review and team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists reputable primary sources and datasets that validate Xeris Biopharma’s market, pricing, and competitive assumptions for fast, traceable decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChicago headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. is headquartered in Chicago, Illinois, giving it one central U.S. base for decision-making and control.\u003c\/p\u003e\n\u003cp\u003eThe Chicago headquarters supports corporate, commercial, and development functions, so teams can coordinate across the company’s U.S.-based operating model.\u003c\/p\u003e\n\u003cp\u003eThat setup matters for a specialty biotech with one main HQ hub and direct oversight of U.S. execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist-prescriber channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. sells its therapies mainly through endocrinologists, neurologists, and other specialists, making this the core access path for rare-disease prescriptions. In 2025, specialist-led management remained critical for products like Gvoke, Recorlev, and Keveyis, where diagnosis and referral drive starts and follow-up drives persistence. This channel works best when specialists manage dosing, monitoring, and refills over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. uses specialty pharmacy and prescription fulfillment for its high-touch products, which fits complex and rare-disease care. These channels help control cold-chain inventory, speed prior authorization, and guide patient onboarding. For Xeris, this matters because specialty pharmacies handled about 70% of U.S. prescription drug spend in 2025, so access and refill flow can drive revenue fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient access support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. supports patient access with reimbursement help and fulfillment coordination, which cuts delays between a script and the first fill. For specialty drugs, benefits investigation and copay help can reduce out-of-pocket friction and improve start rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement support\u003c\/li\u003e\n\u003cli\u003eBenefits investigation\u003c\/li\u003e\n\u003cli\u003eCopay assistance\u003c\/li\u003e\n\u003cli\u003eFaster dispense path\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. commercial footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. keeps its commercial footprint mostly in the U.S., where all 3 marketed products, Gvoke, Keveyis, and Recorlev, are sold through prescription channels. That fits a specialist-led model: in 2025, the company did not rely on broad retail shelf space, but on targeted physician and payer access.\u003c\/p\u003e\n\u003cp\u003eIts U.S.-first setup helps it focus on endocrinology and rare-disease prescribers, where treatment decisions are clinic-driven and reimbursement matters more than mass consumer reach. One clean read: Xeris sells into a narrow but high-value domestic market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S.-led, prescription-only model\u003c\/li\u003e\n\u003cli\u003eThree marketed products in 2025\u003c\/li\u003e\n\u003cli\u003eSpecialist access over retail placement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris’ U.S.-First Channel Strategy Fuels Specialty Drug Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. uses a U.S.-first place strategy: Chicago HQ for control, and specialist-plus-specialty-pharmacy channels for access to Gvoke, Keveyis, and Recorlev. In 2025, specialty pharmacies handled about 70% of U.S. prescription drug spend, so reimbursement help and refill flow are key to starts and persistence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace lever\u003c\/th\u003e\n\u003cth\u003eKey 2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeadquarters\u003c\/td\u003e\n\u003ctd\u003eChicago, Illinois\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eSpecialists and specialty pharmacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket focus\u003c\/td\u003e\n\u003ctd\u003eU.S.-only marketed products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustry context\u003c\/td\u003e\n\u003ctd\u003e~70% of U.S. Rx spend via specialty pharmacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eXeris Biopharma Holdings, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Xeris Biopharma 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises, fully complete and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHCP education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. uses HCP education to teach diagnosis, treatment use, and product handling across its 3 marketed products, which matters in rare diseases where awareness is often low. The message centers on clinical utility and simple administration, especially for products like Gvoke and Recorlev. This kind of promotion helps close knowledge gaps and supports correct use at the point of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare-disease awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. uses rare-disease awareness to flag severe hypoglycemia, periodic paralysis, and Cushing’s syndrome, which are often missed in routine care. This matters: Cushing’s syndrome affects about 10 to 15 people per million each year, and periodic paralysis is also rare and underdiagnosed. By educating patients and clinicians, Xeris Biopharma Holdings, Inc. helps speed specialist referral and treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCongress and conference activity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCongress and conference activity lets Xeris Biopharma Holdings, Inc. show clinical data where prescribers look for proof, especially at endocrinology, neurology, and gastroenterology meetings. These events matter in specialty pharma because peer-to-peer discussion drives trust faster than ads. In 2025, Xeris kept leaning on a focused specialty model, making scientific congresses a low-cost, high-credibility promotion channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient support programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient support programs are a key part of Xeris Biopharma Holdings, Inc.'s promotion mix because specialty drugs often fail at the access step, not the science step. These services usually cover onboarding, injection or use training, and insurance or prior-authorization help, which keeps patients connected after the prescription is written.\u003c\/p\u003e\n\u003cp\u003eFor Xeris Biopharma Holdings, Inc., that matters because persistent support can reduce drop-off in high-friction therapies and help protect refill flow. In specialty care, even small gains in access and adherence can have an outsized sales impact.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnboarding, training, and insurance help drive persistence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital and field marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. likely uses a blended promotion model that pairs digital outreach with field specialists, which fits its 3-product portfolio: Gvoke, Recorlev, and Keveyis. Digital channels can scale education to clinicians and caregivers fast, while field reps focus on high-value specialty accounts where prescribing is concentrated.\u003c\/p\u003e\n\u003cp\u003eThis matters because Xeris serves narrow, hard-to-reach patient groups, so targeted promotion is more efficient than broad consumer marketing. For rare and specialty therapies, field access and payer support often drive adoption more than mass reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses digital to broaden clinician reach.\u003c\/li\u003e\n\u003cli\u003eUses field teams for key accounts.\u003c\/li\u003e\n\u003cli\u003eFits specialty and rare-disease demand.\u003c\/li\u003e\n\u003cli\u003eSupports focused prescribing conversations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris Wins Rare-Disease Demand With Education and Access Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. promotes Gvoke, Recorlev, and Keveyis through HCP education, congresses, digital outreach, and patient support. That fits rare-disease care, where Cushing’s syndrome affects about 10 to 15 people per million each year and awareness is low.\u003c\/p\u003e\n\u003cp\u003eThe focus is on clinical proof, simple use, and access help, not mass advertising. In specialty drugs, training and payer support can matter as much as the prescription.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP education\u003c\/td\u003e\n\u003ctd\u003eUse, diagnosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCongresses\u003c\/td\u003e\n\u003ctd\u003eClinical data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport services\u003c\/td\u003e\n\u003ctd\u003eAccess, adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty-drug pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. prices specialty therapies at premium prescription levels because demand is small and value comes from rare-disease control and easier use. In 2024, Xeris reported about $205 million in net product revenue, showing these drugs are sold as high-value branded therapies, not consumer-priced items. For products like Recorlev, Gvoke, and Keveyis, access and reimbursement matter more than shelf-price cuts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement-driven access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces reimbursement-driven access, so net price depends on payer contracts, prior authorization, and specialty pharmacy routing. In 2025, Medicare Part D lowered patient exposure with a $2,000 out-of-pocket cap, but commercial plans still set the real net realized price through rebates and coverage terms. That is standard for orphan and specialty drugs, where access can hinge on approval speed as much as list price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCopay support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCopay support helps eligible commercially insured patients cut out-of-pocket costs, which can speed Xeris Biopharma Holdings, Inc. treatment starts and lift refill adherence. This matters in rare disease, where about 1 in 10 people in the U.S. is affected and delays can be costly. Lower upfront cost can also reduce abandonment at the pharmacy counter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGross-to-net deductions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. faces gross-to-net deductions from rebates, chargebacks, copay support, and other discounts, so realized revenue is below list price. In specialty drugs, these deductions often eat 15% to 30%+ of gross sales, which makes pricing power look stronger than cash realized.\u003c\/p\u003e\n\u003cp\u003eFor Xeris, that means the key metric is net product revenue, not sticker price. The company’s 2025 filing should be the main source for exact gross-to-net rates and payer mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower net revenue than list price\u003c\/li\u003e\n\u003cli\u003eDriven by rebates and discounts\u003c\/li\u003e\n\u003cli\u003eCommon in specialty biopharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValue-based positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. prices on clinical value, speed of use, and the cost of untreated disease, so the pull comes from medical need, not volume. That fits rare-disease therapy, where Xeris reported more than $200M in 2024 revenue across Recorlev, Gvoke, and Keveyis.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium pricing\u003c\/li\u003e\n\u003cli\u003eNeed-driven demand\u003c\/li\u003e\n\u003cli\u003eRare-disease fit\u003c\/li\u003e\n\u003cli\u003eValue over volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris’ Premium Drug Pricing Hinges on Reimbursement, Not Sticker Price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. uses premium specialty-drug pricing, so net price is driven by reimbursement, rebates, and specialty pharmacy terms more than sticker price. In 2024, net product revenue was about $205 million, and products like Recorlev, Gvoke, and Keveyis sold on clinical value, not volume. The 2025 Medicare Part D $2,000 out-of-pocket cap helps patients, but commercial payer contracts still set realized price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net product revenue\u003c\/td\u003e\n\u003ctd\u003e$205 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Medicare Part D cap\u003c\/td\u003e\n\u003ctd\u003e$2,000 OOP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePricing model\u003c\/td\u003e\n\u003ctd\u003ePremium specialty therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235214401801,"sku":"xers-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/xers-marketing-mix.webp?v=1785736474","url":"https:\/\/dcfanalyst.com\/products\/xers-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}